Lonza Antharis Dual-Payload ADC License | Lucid Diligence Brief
Lonza and Antharis license dual-payload ADC technology for gastrointestinal…
Public Health Today—June 5, 2026
This weekly update in Public Health highlights major developments across…
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B
Lucid Diligence Brief: Bayer to Acquire Perfuse Therapeutics for Up to $2.45B…
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership
Lucid Diligence Brief: Merck × Google Cloud agentic AI partnership Professional…
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A
Lucid Diligence Brief: Beeline Medicines debuts with $300M Series A…
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership
Lucid Diligence Brief: InSilico Medicine and Lilly global partnership…
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery deal
Lucid Diligence Brief: Quotient and MSD ink a $2.2 billion IBD drug discovery…
Lucid Diligence Brief: kyron.bio x Servier strategic partnership
Lucid Diligence Brief: kyron.bio x Servier strategic partnership Professional…
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from CTFH
Lucid Diligence Brief: Formation Bio licenses miR-124 activator FHND5032 from…
Immunology Weekly News - September 17th 2025
🔬 This week in Immunology Updates: Immunology Licensing Deal, Phase II SKYWAY…
Rare Diseases Weekly News - September 11th 2025
🧬 This Week in Rare Diseases: Servier Fragile X deal, FDA RDEP, Bylvay Canada…
Rare Diseases Weekly News - September 4th 2025
🧬 This Week in Rare Diseases: FDA Approvals, Global Initiatives, and New…